Clinical Trial: The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002112) titled 'The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies' on May 14.

Brief Summary: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec100 product in the Treatment of Relapsed/Refractory B-cell Malignancies.

Study Start Date: May 23

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-cell Malignancies

Intervention: BIOLOGICAL: LVIVO-TaVec100 product

Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.

Recruitment Status: RECRUITING

Sponsor: The First Affiliated Hospital with Nanjing Medical Universit...